BACKGROUND: Except for patients with gastrointestinal stromal tumors (GIST), systemic chemotherapy in patients with liver metastasis of soft-tissue sarcoma (STS) is not effective. Therefore, all patients with resectable liver metastases underwent surgical therapy. We present our experience with this approach during the last 13 years. METHODS: All patients (n=45) with liver metastasis of STS undergoing surgical therapy were prospectively analyzed. Clinical and histopathological parameters as well as the postoperative course were recorded. Survival data were analyzed by using the Kaplan-Meier method and the log-rank test. RESULTS: Twenty-seven of 45 patients with liver metastasis underwent hepatic resection; 59% of these patients had a solitary metastasis, 22% had two metastases, and 18% had three or more metastatic nodules. The surgical perioperative mortality was 7%. The median survival was 44 (range, 1-123) months, and the 5-year survival was 49%. Repeated resection for recurrent tumor was performed in eight patients, which yielded a median survival of 76 months. CONCLUSIONS: Patients who have hepatic metastases that are functionally and technically resectable should be considered for surgery because this treatment offers the chance for long-term survival (>5 years).
BACKGROUND: Except for patients with gastrointestinal stromal tumors (GIST), systemic chemotherapy in patients with liver metastasis of soft-tissue sarcoma (STS) is not effective. Therefore, all patients with resectable liver metastases underwent surgical therapy. We present our experience with this approach during the last 13 years. METHODS: All patients (n=45) with liver metastasis of STS undergoing surgical therapy were prospectively analyzed. Clinical and histopathological parameters as well as the postoperative course were recorded. Survival data were analyzed by using the Kaplan-Meier method and the log-rank test. RESULTS: Twenty-seven of 45 patients with liver metastasis underwent hepatic resection; 59% of these patients had a solitary metastasis, 22% had two metastases, and 18% had three or more metastatic nodules. The surgical perioperative mortality was 7%. The median survival was 44 (range, 1-123) months, and the 5-year survival was 49%. Repeated resection for recurrent tumor was performed in eight patients, which yielded a median survival of 76 months. CONCLUSIONS:Patients who have hepatic metastases that are functionally and technically resectable should be considered for surgery because this treatment offers the chance for long-term survival (>5 years).
Authors: J M Coindre; P Terrier; L Guillou; V Le Doussal; F Collin; D Ranchère; X Sastre; M O Vilain; F Bonichon; B N'Guyen Bui Journal: Cancer Date: 2001-05-15 Impact factor: 6.860
Authors: Kristoffer W Brudvik; Sameer H Patel; Christina L Roland; Claudius Conrad; Keila E Torres; Kelly K Hunt; Janice N Cormier; Barry W Feig; Thomas A Aloia; Jean-Nicolas Vauthey Journal: J Gastrointest Surg Date: 2015-05-22 Impact factor: 3.452
Authors: Jennifer M Weiss; Steven Attia; Howard H Bailey; Sharon Weber; Johnny Hu; Mark Reichelderfer; Deepak V Gopal Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: Moritz Schmelzle; Claus F Eisenberger; Jan Schulte am Esch; Hanno Matthaei; Markus Krausch; Wolfram T Knoefel Journal: Langenbecks Arch Surg Date: 2009-12-09 Impact factor: 3.445
Authors: Simon S Lo; Susan D Moffatt-Bruce; Laura A Dawson; Roderich E Schwarz; Bin S Teh; Nina A Mayr; Jiade J Lu; John C Grecula; Thomas E Olencki; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2011-05-24 Impact factor: 66.675
Authors: Ravi Marudanayagam; Bynvant Sandhu; M Thamara P R Perera; Phillipe Taniere; Chris Coldham; Simon Bramhall; David Mayer; John Buckels; Darius Mirza Journal: HPB (Oxford) Date: 2011-03-02 Impact factor: 3.647